Harvard Medical School

BLUE CROSS BLUE SHIELD OF MASSACHUSETTS BRINGS FREE ICE SKATING TO THE OVAL ICE SKATING RINK IN WORCESTER

Retrieved on: 
Monday, January 8, 2024

WORCESTER, Mass., Jan. 8, 2024 /PRNewswire/ -- Central Massachusetts skaters will have the opportunity to skate for free at The Oval Ice Skating Rink in Downtown Worcester on five occasions in January and February, courtesy of Blue Cross Blue Shield of Massachusetts ("Blue Cross").

Key Points: 
  • WORCESTER, Mass., Jan. 8, 2024 /PRNewswire/ -- Central Massachusetts skaters will have the opportunity to skate for free at The Oval Ice Skating Rink in Downtown Worcester on five occasions in January and February, courtesy of Blue Cross Blue Shield of Massachusetts ("Blue Cross").
  • The Oval Ice Skating Rink, which reopened in December, has welcomed more than 72,000 skaters since 2012.
  • "We're thankful for the support provided by Blue Cross, including these free-skating events, which significantly contribute to the sense of community that The Oval Ice Skating Rink promotes," said John LaHair, Director of Marketing, for the DCU Center which also manages The Oval Ice Skating Rink.
  • For more information, including weather-related closings, please visit the The Oval Ice Skating Rink's Facebook and Instagram pages or call the Cornerstone Bank Oval Hotline at (508) 929-0777.

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Retrieved on: 
Monday, January 8, 2024

These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS).

Key Points: 
  • These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS).
  • PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period.
  • PET scan findings for two additional EA patients (10 total) are planned to be available in late January.
  • “Six out of the eight na-SPMS EA patients studied so far have seen measurable clinical improvement in their fatigue.

Biotech Industry Veterans Jeff Jonas and Al Robichaud Join Cure Ventures as Partners

Retrieved on: 
Monday, January 8, 2024

Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the appointment of industry leaders Jeff Jonas, M.D.

Key Points: 
  • Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the appointment of industry leaders Jeff Jonas, M.D.
  • and Al Robichaud, Ph.D. as partners to expand the firm’s work with biotech entrepreneurs in developing therapeutics that cure life-altering diseases.
  • It’s clear to me that Cure has the chops to strategically choose its partners and elevate their work.
  • More importantly, he is about as well respected a leader as you can find in our industry,” said Dave Fallace, co-founder and managing partner at Cure Ventures.

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Retrieved on: 
Monday, January 8, 2024

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.

Key Points: 
  • Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.
  • “Calidi continues to expand our Scientific and Medical Advisory Board, adding leading physicians and scientists from the top cancer hospitals and research institutions in the United States,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
  • Dr. Chiocca is a faculty member at Harvard Medical School and leads a laboratory focused on developing novel genetic therapies for malignant brain tumors.
  • from the University of Tennessee and completed his residency and fellowship at UAB Hospital in Neurology and Neuro-oncology.

Medical Education Market size to grow by USD 208.73 billion from 2022 to 2027, Market is fragmented due to the presence of prominent companies like All India Institute of Medical Sciences, KP Bernard J. Tyson School of Medicine and Mayo Clinic, and many m

Retrieved on: 
Friday, January 5, 2024

The medical education market is fragmented owing to the presence of many global and regional companies.

Key Points: 
  • The medical education market is fragmented owing to the presence of many global and regional companies.
  • Download a Sample before buying
    KP Bernard J. Tyson School of Medicine - The company offers medical education such as a Bachelor of Science (BS) in Health Sciences.
  • National University of Singapore - The company offers medical education such as M.D.M.B.A., M.D.Ph.D., M.D.M.P.H., and M.D.MSHCM, and others.
  • The higher education testing and assessment market is estimated to grow at a CAGR of 6.32% between 2022 and 2027.

Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

Retrieved on: 
Thursday, January 4, 2024

Adam Levy will remain in his role as Chief Financial Officer.

Key Points: 
  • Adam Levy will remain in his role as Chief Financial Officer.
  • “With our expanding operations, we have decided to split the functions of Chief Financial Officer and Chief Business Officer into two roles, and we are excited to have Minji join our team.
  • She brings a solid track record of generating value for multiple companies by identifying and executing strategic opportunities,” stated Jon Congleton, Chief Executive Officer of Mineralys.
  • Prior to joining Mineralys, she held the role of Chief Business Officer at Affamed Therapeutics and General Manager at Affamed Digital, and brought multiple products into their pipeline.

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Retrieved on: 
Thursday, January 4, 2024

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.

Key Points: 
  • WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.
  • “Mike is a world-renowned oncologist and clinical researcher who has made countless contributions to the field of cancer immunotherapy.
  • I am delighted to have Mike join our Board at this important time in the clinical development of our WTX-124 and WTX-330 INDUKINE molecules,” said Dan Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics.
  • He has published over 500 scientific and review articles, co-edited five books, and given over 800 lectures worldwide.

Dr. Stephen Oesterle and Dr. Joshua Makower Join Patient Square Capital as Senior Advisors

Retrieved on: 
Thursday, January 4, 2024

MENLO PARK, Calif., Jan. 4, 2024 /PRNewswire/ -- Patient Square Capital , a leading health care investment firm, today announced that Dr. Joshua Makower and Dr. Stephen Oesterle joined as Senior Advisors to the firm.

Key Points: 
  • MENLO PARK, Calif., Jan. 4, 2024 /PRNewswire/ -- Patient Square Capital , a leading health care investment firm, today announced that Dr. Joshua Makower and Dr. Stephen Oesterle joined as Senior Advisors to the firm.
  • Dr. Makower will also be joining the board of Elevage Medical Technologies, a Patient Square portfolio company focused on growth-stage medical technologies.
  • "Dr. Oesterle and Dr. Makower are undisputed leaders, innovators, and investors in the medical technology space," said Neel Varshney, M.D., Founding Partner of Patient Square.
  • "The resources Patient Square has assembled for the ultimate goal of improving patient outcomes are transformational," added Dr. Oesterle.

Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team

Retrieved on: 
Thursday, January 4, 2024

In addition, the Company named Jeff Albers as Executive Chair and member of the Board of Directors.

Key Points: 
  • In addition, the Company named Jeff Albers as Executive Chair and member of the Board of Directors.
  • Mr. Albers currently serves as board chairman at Blueprint Medicines and board director at Kymera Therapeutics and Spyre Therapeutics.
  • Mark Chao, M.D., Ph.D., has been named Chief Medical Officer and Erica Jackson, Ph.D., has been promoted to Chief Discovery Officer.
  • Dr. Chao joins Scorpion from TenSixteen Bio, a precision therapeutics company where he served as Co-Founder and CEO.

ROME Therapeutics Appoints Heike Keilhack, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, January 4, 2024

ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced the appointment of cancer biology and immunology expert Heike Keilhack, Ph.D., as Chief Scientific Officer.

Key Points: 
  • ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced the appointment of cancer biology and immunology expert Heike Keilhack, Ph.D., as Chief Scientific Officer.
  • Dr. Keilhack brings to ROME more than 20 years of experience leading target validation and preclinical and translational efforts for multiple first-in-class therapeutics at both small biotechnology companies and large pharmaceutical companies.
  • “I was drawn to ROME because of its compelling scientific approach to drug discovery and development, as well as its highly talented team of business and scientific leaders,” said Dr. Keilhack.
  • I am excited to work as part of the ROME team as we uncover and advance this science toward helping patients who need new options.”